Cisco CFO: Services...
Health Care: Drugs
Medivation Inc. (MDVN: NASDAQ)
$48.10 0.57 | 1.20%
05/20/13 - 11:01 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 47.53 |
| 52 Week High | 59.24 |
| 52 Week Low | 39.62 |
| Avg. Daily Vol. (Mil) | 1.25 |
| Beta (3 year) | 1.26 |
| Share Related Items | |
| Mkt Cap (Mil) | 3,563.65 |
| Shares Out (Mil) | 74.98 |
| Float (Mil) | 61.41 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.40 |
| Current Ratio | 3.50 |
| LT Debt/ Equity | 3.52 |
| Total Debt / Equity | 3.52 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 18.66 |
| Price/Book | 62.99 |
| Price/Cash Flow | -29.40 |
| Per Share Data | |
| Earnings | -0.93 |
| Sales | 2.55 |
| Book Value | 0.75 |
| Cash Flow | -1.62 |
| Business Summary | |
|---|---|
| Medivation, Inc.is a biopharmaceutical company focused on the development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. | |
| General Information | |
| 525 Market Street
36th Floor San Francisco, CA 94105 |
|
| www.medivation.net | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 111 | |
| CEO: Dr. David T. Hung,M.D. | |
| Short Interest | |
| Current Month (Mil) | 3.67 |
| Previous Month (Mil) | 3.41 |
| Short Interest Ratio (Days) | 3.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -17.80 |
| Return on Investments | -24.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | 4.40 |
| Profit Margin | -33.20 |
Portfolios with MDVN
- Portfolio NameUser Type
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- ContributorRelative Strength Trades fo...
- User2012 performers
- ContributorFive Drug Stock Winners of ...
- ContributorStocks At New 52-Week Highs...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- ContributorCancer Drug Stocks to Trade...
- UserASCO 2010 Part 2
Latest MDVN Headlines from TheStreet
- Medivation Inc. (MDVN): Today's Featured Health Care Mover 04.17.13 | 06:04 pm
- Top Insider Trades: JAKK SPB YELP MDVN 04.10.13 | 09:04 am
- Medivation Inc. (MDVN): Drugs' Featured Underachiever Of The Day 04.08.13 | 05:04 pm
- Medivation Inc. (MDVN): Today's Featured Health Care Laggard 03.11.13 | 05:03 pm
- Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake 03.06.13 | 10:03 am
- Medivation Stock Falls On Unusually High Volume (MDVN) 03.01.13 | 12:03 pm
- Medivation Rises On Unusually High Volume (MDVN) 02.01.13 | 11:02 am
- Medivation Inc. (MDVN): Today's Featured Health Care Laggard 01.30.13 | 05:01 pm
- Medivation Stock Hits New 52-Week High (MDVN) 01.22.13 | 11:01 am
- J.P. Morgan Healthcare Confab Live Blog: Day One 01.07.13 | 07:01 am
Press Releases for MDVN
- Medivation And Pfizer Announce Results From Phase 3 Concert Trial Of Dimebon In Alzheimer’s Disease - Business Wire 01.17.12 | 07:01 am
- Medivation Announces Participation In 13th Annual BIO CEO & Investor Conference - PR Newswire 02.07.11 | 08:02 am
- Medivation Announces Participation In 29th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.11 | 08:01 am
- Medivation Completes Enrollment In Phase 3 'CONCERT' Trial Of Dimebon Added To Donepezil In Patients With Alzheimer's Disease - PR Newswire 12.07.10 | 08:12 am
- Medivation And Astellas Complete Enrollment In Phase 3 Affirm Trial Of MDV3100 In Advanced Prostate Cancer - PR Newswire 11.29.10 | 04:11 pm
- Medivation Announces Third Quarter 2010 Financial Results Teleconference And Webcast On November 5, 2010 - PR Newswire 10.29.10 | 08:10 am
- Medivation Announces Participation In The NewsMakers In The Biotech Industry Conference - PR Newswire 10.19.10 | 08:10 am
- Medivation And Astellas Announce Initiation Of A Second Phase 3 Clinical Trial Of MDV3100 In Advanced Prostate Cancer - PR Newswire 09.29.10 | 08:09 am
- Medivation Announces Participation In The UBS Global Life Sciences Conference - PR Newswire 09.14.10 | 08:09 am
- Medivation Announces Second Quarter 2010 Financial Results Teleconference And Webcast On August 9, 2010 - PR Newswire 08.02.10 | 08:08 am
Partner Headlines for MDVN
- Neutral on Medivation - Analyst Blog - Zacks 12.31.12 | 05:12 pm
- Medivation Loses A Major Patent Dispute; A Blow To The Stock - Seeking Alpha 12.24.12 | 09:12 am
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
- Therapeutic Proteins Offer New Investment Opportunities - Seeking Alpha 11.24.12 | 05:11 am
- MDVN's Xtandi Off to a Strong Start - Analyst Blog - Zacks 11.13.12 | 09:11 am
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Medivation - Benzinga 11.12.12 | 09:11 am
- After-Hours Earnings Report for November 9, 2012 : MDVN, CRDN, LVB, SYUT, CWCO, WAVX - NASDAQ 11.09.12 | 07:11 pm
- 5 Big Buys By Columbus Circle Investors - Seeking Alpha 11.04.12 | 07:11 am
- Medivation-Astellas Launch Xtandi - Analyst Blog - NASDAQ 09.17.12 | 08:09 pm
- Medivation's Xtandi Approved - Analyst Blog - NASDAQ 09.04.12 | 07:09 pm
